Medical News

RSS

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Female cancer survivors benefit from natural nutritional supplement

A natural nutritional supplement, marketed for the last decade as a sexual aid, has been shown to significantly improve overall quality of life for female cancer survivors, according to researchers at Wake Forest Baptist Medical Center.

7 Jun 2011

FDA issues revised PDUFA date for Lannett's Morphine Sulfate Oral Solution NDA

Lannett Company, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution

7 Jun 2011

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

According to the American Cancer Society, more than 11.4 million Americans are currently living with cancer. While cancer treatments are plentiful, many have negative side effects. Previous studies have indicated that a significant number of patients who receive chemotherapy also experience cognitive declines, including decreases in verbal fluency and memory.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Testosterone spray may slow cognitive decline in post-menopausal women

Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.

7 Jun 2011

Women with low bone density more likely to benefit from bisphosphonate drug

Women with low bone density are seven times more likely to benefit from a bisphosphonate drug when their vitamin D blood levels are above recent recommendations from the Institute of Medicine (IOM) as adequate for bone health.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Researchers reveal surprising link between cell's skeleton and organ size

A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.

7 Jun 2011

David Cameron’s NHS promises

Prime Minister David Cameron gives out “five guarantees” regarding the future of the NHS in England amid details of when changes to planned reforms will be considered. He promised that NHS will remain free at the point of use, care will be improved and budgets will rise and waiting times will be “kept low”.

7 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Thermo Fisher Scientific unveils three new mass spectrometry products at 59th Annual ASMS Conference

Thermo Fisher Scientific Inc., the world leader in serving science, introduced three breakthrough instruments that take mass spectrometry (MS) analysis to new levels of performance in resolution, speed, sensitivity and accuracy. The new instruments were unveiled at the 59th Annual ASMS Conference on Mass Spectrometry and Allied Topics, being held June 5-9 at the Colorado Convention Center.

From Thermo Fisher Scientific Inc. 7 Jun 2011

Jindal's Medicaid plan questioned; Wash. lawmakers enact fee on nursing homes to increase federal match

Calling it a "dubious privatization venture," a Baton Rouge good-government group last week questioned Gov. Bobby Jindal's plan to turn over large chunks of the state Medicaid program to private insurers and praised the Louisiana House of Representatives for trying to slow the process.

7 Jun 2011

HIV positive man puts three women at risk

An HIV-positive man, John Choul Chan, 42, of Findon, South Australia, admitted to endangering the lives of three women through unprotected sex.

7 Jun 2011

Manhattan acquires Senior Scientific

In a move to accelerate applications of a novel cancer detection and treatment technology, Manhattan Scientifics today announced that it has acquired all of Senior Scientific, LLC and its affiliate Scientific Nanomedicine Inc.

7 Jun 2011

Gay, bisexual teenagers more likely to engage in risky behavior

A new report finds that gay, lesbian and bisexual high school students are more likely than heterosexual students to engage in such risky behavior as smoking, drinking alcohol and carrying guns. The study by the Centers for Disease Control and Prevention (CDC) surveyed 156,000 high school students and was released on Monday. This is the largest of its kind by the federal government.

7 Jun 2011

Flaxseed of no use in menopausal hot flashes: Study

Flaxseed has been the latest agent that has been tried in treating menopausal hot flashes and it is seen that it does not reduce the incidence of the unpleasant symptoms.

7 Jun 2011

Actavis receives final FDA approval for Zolpidem ER Tablets

Actavis, an international generic pharmaceuticals company, today announced that it has received final approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV. Distribution of the product has commenced.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011